Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Outfitter Financial LLC

Outfitter Financial LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 32.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,610 shares of the company’s stock after buying an additional 2,815 shares during the quarter. Outfitter Financial LLC’s holdings in Novo Nordisk A/S were worth $806,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL raised its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $29,000. Transce3nd LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $33,000. North Capital Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $27,000. Finally, Copeland Capital Management LLC raised its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating for the company. BMO Capital Markets reissued a “market perform” rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $112.00.

Novo Nordisk A/S Trading Down 0.9%

Shares of NYSE:NVO traded down $0.56 during trading on Friday, reaching $64.73. 1,502,154 shares of the stock were exchanged, compared to its average volume of 7,348,532. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $139.74. The firm has a market cap of $289.04 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 1.29 and a beta of 0.64. The firm’s 50-day moving average price is $70.37 and its 200 day moving average price is $74.53.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.